- Home
- UROY vs SOPH Comparison
UROY vs SOPH Comparison
Compare UROY & SOPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | UROY | SOPH |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | Canada | Switzerland |
| Employees | 14 | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 404.6M | 462.3M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | UROY | SOPH |
|---|---|---|
| Price | $3.03 | $6.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | ★ 2.2M | 387.6K |
| Earning Date | 03-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $279.20 | $23.09 |
| Revenue Next Year | N/A | $19.57 |
| P/E Ratio | $1,584.46 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.42 | $2.92 |
| 52 Week High | $5.52 | $6.74 |
Technical Indicators
Market Signals| Indicator | UROY | SOPH |
|---|---|---|
| Relative Strength Index (RSI) | 55.79 | 68.45 |
| Support Level | $2.67 | $4.63 |
| Resistance Level | $4.01 | N/A |
| Average True Range (ATR) | 0.15 | 0.37 |
| MACD | 0.06 | 0.07 |
| Stochastic Oscillator | 89.32 | 79.12 |
Price Performance
Historical ComparisonAbout UROY Uranium Royalty Corp.
Uranium Royalty Corp is focused on gaining exposure to uranium prices by making investments in uranium interests, including royalties, streams, debt and equity investments in uranium companies, and through holdings of physical uranium. The company operates in a single segment that is acquiring and assembling a portfolio of royalties, investing in companies with exposure to uranium and physical uranium. The Company also engages in the purchase and sale of physical uranium.
About SOPH SOPHiA GENETICS SA
Sophia Genetics SA is a healthcare technology company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It has built a cloud-based SaaS platform capable of analyzing data and generating insights from complex multimodal data sets and different diagnostic modalities. The Company had a physical presence in three countries outside of its headquarters in Switzerland: France, the United States, and Brazil.